Clinical trial of optimized regimen of Chinese traditional medicine in differentiation and treatment of patients with stage 3 chronic kidney disease

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-08000204

Enrollment

Unknown

Registered

2008-12-02

Start date

2007-12-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary glomerular disease, chronic kidney disease(stage 3)

Interventions

Chinese medicine + western medicine group:Oral Chinese medicine granules based on TCM "zheng", 1 bag, 2/d. combined with oral benazepril, 1 tablet/d, totally 24 weeks

western medicine group:oral benazepr

Chinese medicine group:oral Chinese medicine granules based on different TCM "zhengs", 1 bag,2/d, totally 24 weeks

Eligibility

Sex/Gender

Male

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. CKD patients (primary glomerular disease), GFR30~59ml/min; 2. chronic kidney disease (stage 3) with TCM "zhengs" include both "qi xu" and "yin xu" (deficiency of “qi” and "yin", "yu zheng" (stasis of blood or "qi", "feng shi zheng" (wind-dampness), "shi re zheng" (damp-heat); 3. 24h proteinuria <=2.0g/d; 4. Blood pressure less than 140/90mmHg with non ACEI/ARB antihypertensive medication; 5. ARB/ACEI should be discontinuation for 2 weeks of eluting in the patients who have received ACEI/ARB.

Exclusion criteria

Exclusion criteria: 1. Renal injury due to secondary glomerular disease; 2. Patients with primary severe heart, brain, lung, liver, hematopoietic system disease; 3. 24h proteinuria >2.0g/d; 4. Severe anemia, Hgb<80g/L; 5. Patients diagnosed with acute renal failure; 6. Patients with renal transplantation; 7. Patients with mental disease; 8. Pregnant patients or women need fertilization, women in lactation period; 9. Patients allergic to the drug used in this study; l0. Patients with HBeAg(+); 11. Patients enrolled in another clinical trial; 12. Patients treated with steroid and immunorepressor.

Design outcomes

Primary

Measure	Time frame
morning urinary Alb/Cr;eGFR;incidence of endpoint events (Scr double, ESRD, death;24h urinary protein excretion;	—

Secondary

Measure	Time frame
serum uric acid;serum albumin;blood BUN;TCM "zheng" score;hemoglobin;	—

Countries

China

Contacts

Public ContactWang YongJun

hz_luying@126.com+86 0571 85827682

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026